Raloxifene for prevention of glucocorticoid-induced bone loss: A 12-month randomised double-blinded placebo-controlled trial

Annals of the Rheumatic Diseases

Volumn 70, Issue 5, 2011, Pages 778-784

  Mok, Chi Chiu ^a   Ying, King Yee ^b   To, Chi Hung ^a   Ho, Ling Yin ^a   Yu, Ka Lung ^a   Lee, Hon Kit ^a   Ma, Kwok Man ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN; PLACEBO; PREDNISOLONE; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROTEIN PRECURSOR; RALOXIFENE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUODENUM ULCER; DYSPEPSIA; FEMALE; FEMUR NECK; HEADACHE; HEARTBURN; HIP; HUMAN; LEG CRAMP; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATIC DISEASE; RISK FACTOR; SPINE; THORAX PAIN; THROMBOEMBOLISM; TINNITUS; URINE LEVEL; VERTEBRA FRACTURE; VERTIGO;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HIP JOINT; HUMANS; LIPIDS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PREDNISONE; RALOXIFENE; RHEUMATIC DISEASES;

EID: 79953324523     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.143453     Document Type: Article

References (29)

1. Woolf AD. An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2007;19:370-5. (Pubitemid 46884194)
2. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006;39:253-9. (Pubitemid 43870263)
3. Kaji H, Yamauchi M, Chihara K, et al. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 2006;53:27-34.
4. van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000;39:1383-9. (Pubitemid 32045866)
5. De Vries F, Bracke M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007;56:208-14. (Pubitemid 46106193)
6. Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy:arrest of bone loss. Ann Rheum Dis 2009;68:373-6.
7. Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int 2010;21:1287-93.
8. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis:results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000;43:522-30. (Pubitemid 30394942)
9. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515-26.
10. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11. (Pubitemid 32113136)
11. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
12. Reid DM, Devogelaer JP, Saag K, et al.;HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-63.
13. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39. (Pubitemid 350106710)
14. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45. (Pubitemid 29384151)
15. Delmas PD, Ensrud KE, Adachi JD, et al.; Mulitple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17. (Pubitemid 34879503)
16. Mok CC, To CH, Mak A, et al. Raloxifene for postmenopausal women with systemic lupus erythematosus:a pilot randomized controlled study. Arthritis Rheum 2005;52:3997-4002. (Pubitemid 41798239)
17. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468-89. (Pubitemid 28486716)
18. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010;6:82-8.
19. Sivagurunathan S, Muir MM, Brennan TC, et al. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 2005;20:390-8. (Pubitemid 40293487)
20. Eijken M, Meijer IM, Westbroek I, et al. Wnt signaling acts and is regulated in a human osteoblast differentiation dependent manner. J Cell Biochem 2008;104:568-79. (Pubitemid 351671645)
21. Chua CC, Chua BH, Chen Z, et al. Dexamethasone induces caspase activation in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta 2003;1642:79-85. (Pubitemid 37338281)
22. Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002;30:368-76. (Pubitemid 34150159)
23. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7. (Pubitemid 27510100)
24. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10. (Pubitemid 33150990)
25. Johnston CC, Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women:three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444-50.
26. Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004;164:871-9. (Pubitemid 38520628)
27. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial:results of subgroup analyses by age and other factors. Circulation 2009;119:922-30.
28. Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009;40:147-55.
29. Kung AW, Chao HT, Huang KE, et al. Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. J Clin Endocrinol Metab 2003;88:3130-6. (Pubitemid 36877483)